ArticlePacing and clinical electrophysiology : PACE2025
Development and Validation of a Mortality Prediction Model for Left Ventricular Thrombus.
Article in Pacing and clinical electrophysiology : PACE, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and Validation of a Mortality Prediction Model for Left Ventricular Thrombus.Pacing and clinical electrophysiology : PACE · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveLeft ventricular thrombus (LVT) is a severe complication associated with increased risks of systemic embolism and mortality. Despite advancements in anticoagulant therapy, optimal management strategies and risk factors for all-cause mortality remain unclear. This study aims to develop a predictive model to assess mortality risk in LVT patients and guide clinical decision-making. METHODS AND
resultsThis retrospective cohort study included LVT patients diagnosed at West China Hospital (June 2018-June 2023). Patients were classified into survival and mortality groups based on all-cause mortality during follow-up. A total of 459 patients were included, randomly divided into training (n = 322) and validation (n = 137) sets. Logistic regression analysis identified seven independent predictors of mortality, which were used to construct a nomogram-based risk prediction model. The model demonstrated good discrimination with an area under the receiver operating characteristic curve (AUC) of 0.846 in the training set and 0.791 in the validation set. Key mortality predictors included elevated B-type natriuretic peptide (BNP) (OR 3.359, 95% CI 1.827-6.176, p = 0.0001), lower albumin levels (OR 0.930, 95% CI 0.882-0.981, p = 0.0077), absence of antithrombotic therapy (OR 0.468, 95% CI 0.303-0.723, p = 0.0006), and presence of malignant tumors (OR 6.199, 95% CI 1.593-24.129, p = 0.0085).
conclusionA novel mortality prediction model for LVT patients was developed, offering a valuable tool for risk assessment and treatment optimization. This model provides a valuable tool for risk assessment and treatment optimization in Asian populations, particularly in China. Further validation is required to confirm its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.